496 results on '"LiVolsi VA"'
Search Results
2. The effects of frozen tissue storage conditions on the integrity of RNA and protein
- Author
-
Auer, H, primary, Mobley, JA, additional, Ayers, LW, additional, Bowen, J, additional, Chuaqui, RF, additional, Johnson, LA, additional, Livolsi, VA, additional, Lubensky, IA, additional, McGarvey, D, additional, Monovich, LC, additional, Moskaluk, CA, additional, Rumpel, CA, additional, Sexton, KC, additional, Washington, MK, additional, Wiles, KR, additional, Grizzle, WE, additional, and Ramirez, NC, additional
- Published
- 2014
- Full Text
- View/download PDF
3. Macrofollicular encapsulated variant of papillary thyroid carcinoma as a potential pitfall in histologic and cytologic diagnosis - A report of three cases
- Author
-
Fadda, G, Fiorino, Mc, Mule, A, and Livolsi, Va
- Published
- 2002
4. Frozen section and the thyroid
- Author
-
Livolsi, Va and Fadda, G
- Subjects
THYROID NEOPLASMS ,HISTOLOGY ,INTRAOPERATIVE EXAMINATION - Published
- 2001
5. Usefulness of ultrafast Papanicolaou-stained scrape preparations in intraoperative management of thyroid lesions
- Author
-
Basolo, Fulvio, Baloch, Zw, Baldanzi, A, Miccoli, Paolo, and Livolsi, Va
- Published
- 1999
6. CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma.
- Author
-
Cameselle-Teijeiro J, Alberte-Lista L, Peteiro-González D, Abdulkader-Nallib I, Reyes-Santías R, Soares P, Sobrinho-Simoes M, Enriquez M, Baloch Z, Montone K, Zhang P, and Livolsi VA
- Published
- 2012
- Full Text
- View/download PDF
7. The ability to evaluate prognostic variables on frozen section in hysterectomies performed for endometrial carcinoma
- Author
-
Noumoff, JS, primary, Menzin, A, additional, Mikuta, J, additional, Lusk, EJ, additional, Morgan, M, additional, and LiVolsi, VA, additional
- Published
- 1992
- Full Text
- View/download PDF
8. Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control.
- Author
-
Weinstein GS, Quon H, Newman HJ, Chalian JA, Malloy K, Lin A, Desai A, Livolsi VA, Montone KT, Cohen KR, and O'Malley BW
- Published
- 2012
9. Malignant struma ovarli
- Author
-
Rosenblum, NG, primary, LiVolsi, VA, additional, Edmonds, PR, additional, and Mikuta, JJ, additional
- Published
- 1989
- Full Text
- View/download PDF
10. Peritoneal cytology in gynecologic cancer: an essential adjunct.
- Author
-
LiVolsi VA and LiVolsi, V A
- Published
- 1996
- Full Text
- View/download PDF
11. Corticomedullary mixed tumor of the adrenal gland with concurrent adrenal myelolipoma.
- Author
-
Chu AY, Livolsi VA, Fraker DL, and Zhang PJ
- Abstract
We report the case of a corticomedullary mixed tumor of the adrenal gland in a 55-year-old woman with a left adrenal mass who presented with mild symptoms of Cushing syndrome and an elevated urinary cortisol level. The patient underwent a left adrenalectomy. A well-circumscribed 2.5-cm mass, composed of an admixture of adrenal cortical cells and pheochromocytes, and an incidental 0.7cm myelolipoma were present in the resected left adrenal gland. The diagnosis of adrenal corticomedullary mixed tumor was confirmed by both immunohistochemistry and electron microscopy. To our knowledge, this is the eighth well-documented report of this rare tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
12. Author reply.
- Author
-
Tomaszewski, John E., LiVolsi, Virginia A., Tomaszewski, JE, and LiVolsi, VA
- Published
- 2000
- Full Text
- View/download PDF
13. The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review.
- Author
-
Montone KT, Baloch ZW, and LiVolsi VA
- Published
- 2008
- Full Text
- View/download PDF
14. Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates.
- Author
-
Khurana KK, Truong LD, Livolsi VA, and Baloch ZW
- Abstract
Context.--Immunohistochemical staining for cytokeratin 19 (CK-19) is a useful ancillary technique for diagnosing papillary thyroid carcinoma (papillary carcinoma) in histologic specimens. Although similar results have been obtained on aspirate smears, to our knowledge the utility of CK-19 immunolocalization in cell block preparations as an adjunct to fine-needle aspiration diagnosis of papillary carcinoma has not been examined. Objective.--The purpose of this study was to determine whether CK-19 immunostaining of cell block preparations of thyroid aspirates is a useful ancillary technique for diagnosing papillary carcinoma. Materials and Methods.--Using a monoclonal antibody to CK-19 and a standard avidin-biotin complex technique, immunostaining was performed on paraffin-embedded cell blocks of 57 cases with the following cytologic diagnoses: (a) papillary carcinoma (20 cases); (b) atypical cytology, cannot exclude papillary carcinoma (19 cases); and (c) nonneoplastic thyroid (18 cases). The staining reaction in each case was graded on the basis of percentage of epithelial cells stained (1+, <10%; 2+, <10%-50%; 31, >50). Tissue follow-up was available in all cases. Results.--Nineteen (95%) of 20 cases with an unequivocal diagnosis of papillary carcinoma were positive for CK-19 (3+). Tissue follow-up confirmed papillary carcinoma in all 20 cases. Of the 19 cases with a diagnosis of atypical cytology, cannot exclude papillary carcinoma, 7 (37%) cases displayed 3+ immunostaining and subsequent excision confirmed papillary carcinoma in all 7 cases. The remaining 12 cases with 1+ immunostaining included surgically confirmed goiter (6 cases), adenoma (2 cases), lymphocytic thyroiditis (3 cases), and papillary carcinoma (1 case). The follicular cells in 18 cases with a cytologic diagnosis of nonneoplastic thyroid showed 1+ immunostaining. Histologic follow-up of these cases confirmed the non-neoplastic cytologic diagnoses. Conclusions... [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
15. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
- Author
-
Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, and Haugen BR
- Published
- 2012
16. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
- Author
-
Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, and Boyd J
- Published
- 1996
17. A comparison of the histopathologic features of thyroid carcinomas with NTRK fusions to those with other malignant fusions.
- Author
-
Tondi Resta I, Rind A, Montone KT, Livolsi VA, and Baloch ZW
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Biomarkers, Tumor genetics, Oncogene Proteins, Fusion genetics, Gene Fusion, Young Adult, Receptor, trkC genetics, Biopsy, Fine-Needle, Aged, 80 and over, Genetic Predisposition to Disease, Adolescent, Thyroid Neoplasms genetics, Thyroid Neoplasms pathology, Receptor, trkA genetics
- Abstract
Background: Chromosomal rearrangements involving one of the NTRK genes result in oncogenic driver mutations in thyroid carcinoma (TC) and serve as a target for therapy. We compared the clinicopathologic features of thyroid carcinomas with NTRK fusions vs. thyroid neoplasms with other malignancy associated gene fusions within our institution., Materials and Methods: Our pathology archives were searched from 2013 to 2023 for thyroid neoplasms with gene fusions, excluding THADA fusions and medullary thyroid carcinomas., Results: 55 thyroid lesions were identified: 22 with NTRK fusions (NTRK cohort) and 33 with other fusions (non-NTRK cohort). On fine needle aspiration (FNA), 54% of the NTRK cohort were classified as Category V as per Bethesda System for Reporting Thyroid Cytology (TBSRTC) and 51.5% of non-NTRK cohort as TBSRTC Category III. In the NTRK cohort, the most common reported fusion was ETV6::NTRK3 and the most common reported fusion in the non-NTRK cohort was PAX8::PPAR-gamma. On histologic examination both cohorts were most commonly diagnosed as PTC follicular variant. Invasive features were more common in the NTRK cohort in comparison to the non-NTRK cohort. Locoregional recurrence occurred in 2/22 NTRK cases and 2/33 non-NTRK cases, with average time from surgery to recurrence being 5.5 months and 21 months, respectively. The majority of patients in both groups are alive with no evidence of disease., Conclusions: Thyroid neoplasms with a malignancy associated gene fusion are likely to be diagnosed as subtype/variant of PTC. Patients whose thyroid lesions harbor NTRK fusions present with a PTC-FV that on presentation has more aggressive clinicopathologic findings and are likely to have earlier disease recurrence., Competing Interests: Declaration of competing interest The authors of this manuscript have no conflicts of interest to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
- Author
-
Williams MD, Liu Z, Rossi ED, Agarwal S, Ryška A, Ghuzlan AA, Bychkov A, Baloch Z, Chernock R, Chiosea SL, Cipriani NA, Erkilic S, Fridman M, Hang JF, Harahap AS, Jung CK, Kakudo K, Khalil M, Khanafshar E, Kumarasinghe P, Lloyd R, Nguyen TP, Ocal IT, Prasad ML, Pusztaszeri M, Rana C, Sadow P, Sajed DP, Seethala R, Tallini G, Vuong HG, Yegen G, LiVolsi VA, and Nikiforov YE
- Abstract
Context: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced as a new entity replacing the diagnosis of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC). Significant variability in the incidence of NIFTP diagnosed in different world regions has been reported., Objective: To investigate the rate of adoption of NIFTP, change in practice patterns, and uniformity in applying diagnostic criteria among pathologists practicing in different regions., Methods: Two surveys distributed to pathologists of the International Endocrine Pathology Discussion Group with multiple-choice questions on NIFTP adoption into pathology practice and whole slide images of 5 tumors to collect information on nuclear score and diagnosis. Forty-eight endocrine pathologists, including 24 from North America, 8 from Europe, and 16 from Asia/Oceania completed the first survey and 38 the second survey., Results: A 94% adoption rate of NIFTP by the pathologists was found. Yet, the frequency of rendering NIFTP diagnosis was significantly higher in North America than in other regions (P = .009). While the highest concordance was found in diagnosing lesions with mildly or well-developed PTC-like nuclei, there was significant variability in nuclear scoring and diagnosing NIFTP for tumors with moderate nuclear changes (nuclear score 2) (case 2, P < .05). Pathologists practicing in North America and Europe showed a tendency for lower thresholds for PTC-like nuclei and NIFTP than those practicing in Asia/Oceania., Conclusion: Despite a high adoption rate of NIFTP across geographic regions, NIFTP is diagnosed more often by pathologists in North America. Significant differences remain in diagnosing intermediate PTC-like nuclei and respectively NIFTP, with more conservative nuclear scoring in Asia/Oceania, which may explain the geographic differences in NIFTP incidence., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
19. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
- Author
-
Yang SP, Nga ME, Bundele MM, Chiosea SI, Tan SH, Lum JHY, Parameswaran R, Lim MY, Li H, Cheah WK, Sek KS, Tan ATH, Loh TKS, Ngiam KY, Tan WB, Huang X, Ho TWT, Lim KH, Lim CM, Singaporewalla RM, Rao AD, Rao NCL, Chua DYK, Chin DC, Wald AI, LiVolsi VA, Nikiforov YE, and Tai ES
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Young Adult, Asia, Southeastern, Biomarkers, Tumor genetics, Biopsy, Fine-Needle, Genomics methods, Mutation, Prognosis, Prospective Studies, Southeast Asian People, Thyroid Neoplasms genetics, Thyroid Neoplasms pathology, Thyroid Neoplasms diagnosis, Thyroid Nodule genetics, Thyroid Nodule pathology, Thyroid Nodule diagnosis
- Abstract
Background: Most thyroid nodules are benign. It is important to determine the likelihood of malignancy in such nodules to avoid unnecessary surgery. The primary objective of this study was to characterize the genetic landscape and the performance of a multigene genomic classifier in fine-needle aspiration (FNA) biopsies of cytologically indeterminate thyroid nodules in a Southeast Asian cohort. The secondary objective was to assess the predictive contribution of clinical characteristics to thyroid malignancy., Methods: This prospective, multicenter, blinded study included 132 patients with 134 nodules. Molecular testing (MT) with ThyroSeq v3 was performed on clinical or ex-vivo FNA samples. Centralized pathology review also was performed., Results: Of 134 nodules, consisting of 61% Bethesda category III, 20% category IV, and 19% category V cytology, and 56% were histologically malignant. ThyroSeq yielded negative results in 37.3% of all FNA samples and in 42% of Bethesda category III-IV cytology nodules. Most positive samples had RAS-like (41.7%), followed by BRAF-like (22.6%), and high-risk (17.9%) alterations. Compared with North American patients, the authors observed a higher proportion of RAS-like mutations, specifically NRAS, in Bethesda categories III and IV and more BRAF-like mutations in Bethesda category III. The test had sensitivity, specificity, negative predictive value, and positive predictive value of 89.6%, 73.7%, 84.0%, and 82.1%, respectively. The risk of malignancy was predicted by positive MT and high-suspicion ultrasound characteristics according to American Thyroid Association criteria., Conclusions: Even in the current Southeast Asian cohort with nodules that had a high pretest cancer probability, MT could lead to potential avoidance of diagnostic surgery in 42% of patients with Bethesda category III-IV nodules. MT positivity was a stronger predictor of malignancy than clinical parameters., (© 2024 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
20. Differentiated high grade thyroid carcinomas: Diagnostic consideration and clinical features.
- Author
-
Tondi Resta I, Gubbiotti MA, Montone KT, Livolsi VA, and Baloch ZW
- Abstract
Background: Differentiated high-grade thyroid carcinomas (DHGTCs) are a new diagnostic entity most recently defined in the 2022 World Health Organization's (WHO) Classification of Endocrine and Neuroendocrine Tumors. This new entity has been minimally described in the literature, and additional cases classified as such are missing., Materials and Methods: Cases of DHGTCs diagnosed at our institution from 2012 to 2022 were identified, and the following were reviewed: cytologic and histologic diagnoses, ancillary testing, immunohistochemical staining, treatments, and patient outcomes. Immunohistochemical staining for Ki67 was performed on selected cases lacking this immunostain. A systematic literature review of the English literature on DHGTCs from 2013 to 2023 was performed using PubMed and Embase., Results: Case cohort included 32 cases of DHGTCs, with an average age of 52.6 years (range 17-84 years) and a male:female ratio of 1.3:1. All cases underwent fine needle aspiration (FNA) and were categorized by The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) as follows: 14 cases as malignant (43.8 %), 10 as follicular neoplasm (31.3 %), 5 as atypia of undetermined significance (15.6 %), 2 as suspicious for malignancy (6.2 %), and 1 as non-diagnostic (3.1 %). The average tumor size was 5.15 cm, and most were papillary thyroid carcinoma (28, 87.5 %), with classic subtype being the most common. Twenty-one cases revealed tumor necrosis and the mitotic activity in lesions without necrosis averaged to 5.5 mitoses per 2 mm
2 (range 0-7). The average Ki67 proliferative index was 5.6 %. Extrathyroidal extension was seen in 17, angioinvasion in 21, lymphatic invasion in 7, and perineural invasion in 1 case. Foci of solid or trabecular growth were identified in five cases. Lymph node metastases at the time of diagnosis were noted in 10 cases and 7 demonstrated distant metastases or locoregional recurrence. To date, 25 patients are alive, and one has died from disease., Conclusions: Our institutional experience demonstrates that DHGTC is a rare, but aggressive thyroid tumor subtype that requires consideration in the setting of a well-differentiated thyroid neoplasm to appropriately assess for possible disease recurrence and determination of patient prognosis., Competing Interests: Declaration of competing interest The authors of this manuscript have no conflicts of interest to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
21. Insights Obtained from the Nontumorous Glandular Tissue in Patients with Endocrine Tumors.
- Author
-
Tischler AS, LiVolsi VA, and Asa SL
- Subjects
- Humans, Hyperplasia, Genetic Predisposition to Disease, Hormones, Endocrine Gland Neoplasms, Thyroid Neoplasms pathology
- Abstract
The pathology of neoplasia tends to focus on the tumor that requires characterization, grading, and staging. However, nontumorous tissue surrounding the lesion can also provide information, particularly about pathogenetic mechanisms. In endocrine tissues, this takes the form of precursor lesions that characterize several genetic predisposition syndromes. In addition, because of the unique functional aspects of endocrine neoplasia, the nontumorous tissue provides evidence of hormone excess, with hyperplasia and/or atrophy and other involutional changes allowing the pathologist to confirm both hormone function by the tumor and the effects of medical therapies. In this article, we review the various clinically relevant features that should be assessed and reported to enhance clinical management of patients with endocrine neoplasms. For example, in thyroid there may be inflammatory thyroiditis or goiter of various etiologies; there may be C-cell hyperplasia either as a preneoplastic lesion in patients with genetic predisposition to medullary thyroid carcinoma or as a reactive phenomenon. Drug-induced changes can be seen in thyroid and adrenal cortex. In neuroendocrine tissues, the nontumorous tissues may show precursor lesions such as endocrine cell hyperplasia/dysplasia; there may be related or unrelated hyperplastic or neoplastic lesions. Some tissues, such as pituitary corticotrophs and adrenal cortex, develop changes that reflect feedback suppression by hormone excess that can serve as biomarkers of tumor functionality and provide enhanced clinicopathologic correlates., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
22. Neoplasms in Struma Ovarii: A Review.
- Author
-
Tondi Resta I, Sande CM, and LiVolsi VA
- Subjects
- Female, Humans, Thyroid Cancer, Papillary, Ovarian Neoplasms diagnosis, Ovarian Neoplasms pathology, Carcinoid Tumor diagnosis, Carcinoid Tumor pathology, Struma Ovarii diagnosis, Thyroid Neoplasms diagnosis, Thyroid Neoplasms pathology
- Abstract
Struma ovarii is a well-known ovarian teratoma made up of benign thyroid tissue. These lesions demonstrate variable, normal architecture and normal thyroid immunohistochemical staining with positivity for TTF1, PAX8, and thyroglobulin. Though most are benign, some of these lesions can also present with a malignant component. Within this article, we review the most common diagnostic malignancies including papillary thyroid carcinoma, strumal carcinoid, highly differentiated follicular thyroid carcinoma, and other thyroid carcinomas. We additionally review the use of TTF1 staining to assist in differentiating these lesions from surrounding gynecologic epithelium, which is imperative in making such diagnoses. In highlighting these entities, we hope to provide practicing pathologists with an effective and concise review of these lesions to assist in more challenging cases of struma ovarii., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
23. An investigation into noninvasive follicular thyroid neoplasms with papillary-like nuclear features: does the initial proposal on noninvasive follicular thyroid neoplasms with papillary-like nuclear features behavior hold true?
- Author
-
Tondi Resta I, Gubbiotti MA, Montone KT, Livolsi VA, and Baloch ZW
- Subjects
- Humans, Male, Female, Middle Aged, Thyroidectomy, Retrospective Studies, Adenocarcinoma, Follicular pathology, Thyroid Neoplasms pathology, Carcinoma pathology
- Abstract
Current management of patients with noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) is lobectomy with close clinical follow-up. Because this entity is still young, we present our 5-year institutional experience with NIFTP since that time. Cases of NIFTP diagnosed from 2017 to 2022 were identified. Data points including patient demographics, radiology, cytologic and pathologic diagnoses, molecular profiles, and clinical follow-up were documented. A literature review of NIFTP case series was performed. A total of 379 cases were included (mean age: 52 years, female:male ratio 3.3:1). Ultrasound findings were available for 260 patients, and 247 underwent fine-needle aspiration (FNA). The FNA diagnoses per the Bethesda System for Reporting Thyroid Cytology were nondiagnostic (n = 2), benign (n = 16), atypia of undetermined significance/follicular lesion of undetermined significance (n = 119), follicular neoplasm/suspicious for follicular neoplasm (n = 68), suspicious for malignancy (n = 31), and malignant (n = 11). Molecular testing was performed in 179 cases. Lobectomy was performed for 183, total thyroidectomy for 192, and nodulectomy for 4 cases. The average size of NIFTP was 2.3 cm, and 232 cases had additional nodules (including benign and malignant neoplasms). Multifocal NIFTP occurred in 32 patients. Lymph nodes were evaluated in 196 cases with metastatic carcinoma in 29 cases (all with concurrent diagnoses of carcinoma). Most patients were alive at follow-up, 100 were lost to follow-up, and three died from other causes. Literature review revealed 2870 NIFTP cases with similar patient demographics and pathologic findings. We confirm that NIFTP is a low-risk neoplasm with indolent clinical behavior, which can be managed conservatively., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Cancer Research for 35 Years.
- Author
-
McCall SJ, Lubensky IA, Moskaluk CA, Parwani A, Radin K, Ramirez NC, Von Menchhofen Z, Washington MK, and LiVolsi VA
- Subjects
- United States, Humans, National Cancer Institute (U.S.), Biomarkers, Neoplasms
- Abstract
The Cooperative Human Tissue Network was created by the NCI in 1987 to support a coordinated national effort to collect and distribute high quality, pathologist-validated human tissues for cancer research. Since then, the network has expanded to provide different types of tissue samples, blood and body fluid samples, immunohistologic and molecular sample preparations, tissue microarrays, and clinical datasets inclusive of biomarkers and molecular testing. From inception through the end of 2021, the network has distributed 1,375,041 biospecimens. It served 889 active investigators in 2021. The network has also taken steps to begin to optimize the representation of diverse communities among the distributed biospecimens. In this article, the authors review the 35-year history of this network, describe changes to the program over the last 15 years, and provide operational and scientific highlights from each of the divisions. Readers will learn how to engage with the network and about the continued evolution of the program for the future., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
25. Sclerosing Mucoepidermoid Carcinoma with Eosinophilia of the Thyroid and Mucoepidermoid Carcinoma of the Thyroid: What's in a Name?
- Author
-
LiVolsi VA
- Subjects
- Humans, Carcinoma, Mucoepidermoid diagnosis, Carcinoma, Mucoepidermoid pathology, Eosinophilia complications, Eosinophilia pathology, Thyroid Neoplasms complications, Thyroid Neoplasms pathology
- Published
- 2023
- Full Text
- View/download PDF
26. The Thyroid Pathologist Meets Therapeutic Pharmacology.
- Author
-
Sande CM, Tondi Resta I, and Livolsi VA
- Subjects
- Humans, Animals, Rats, Iodine Radioisotopes, Pathologists, Anti-Bacterial Agents pharmacology, Thyroid Neoplasms, Thyroiditis, Iodine
- Abstract
The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug classes for the thyroid pathologist: iodine, antithyroid drugs, psychotropic drugs, antibiotics, cardiotropic drugs, antidiabetic drugs, and immunomodulatory agents. Radioactive iodine initially induces mild histologic changes; however, the long-term effects include marked follicular atrophy, fibrosis, and nuclear atypia-changes that vary depending on the pre-therapy condition of the gland. Some psychotropic drugs have been associated with a spectrum of inflammatory changes throughout the gland. The tetracycline class of antibiotics, namely minocycline, can lead to a grossly black thyroid gland with pigment seen in both colloid and follicular epithelial cells while variably present within thyroid nodules. The surgical pathologist most commonly sees an amiodarone-affected gland removed for hyperthyroidism, and the histologic findings again depend on the pre-therapy condition of the gland. While GLP-1 receptor agonists carry an FDA black box warning for patients with a personal or family history of multiple endocrine neoplasia or medullary thyroid carcinoma, the C cell hyperplasia originally noted in rats has not borne out in human studies. Finally, thyroiditis and hypothyroidism are well known complications of checkpoint inhibitor therapy, and rare cases of severe thyroiditis requiring urgent thyroidectomy have been reported with unique histologic findings. In this review, we describe the histologic findings for these drugs and more, in many cases including their functional consequences., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
27. Ensuring remote diagnostics for pathologists: an open letter to the US Congress.
- Author
-
Lennerz JK, Pantanowitz L, Amin MB, Eltoum IE, Hameed MR, Kalof AN, Khanafshar E, Kunju LP, Lazenby AJ, Montone KT, Otis CN, Reid MD, Staats PN, Whitney-Miller CL, Abendroth CS, Aron M, Birdsong GG, Bleiweiss IJ, Bronner MP, Chapman J, Cipriani NA, de la Roza G, Esposito MJ, Fadare O, Ferrer K, Fletcher CD, Frishberg DP, Garcia FU, Geldenhuys L, Gill RM, Gui D, Halat S, Hameed O, Hornick JL, Huber AR, Jain D, Jhala N, Jorda M, Jorns JM, Kaplan J, Khalifa MA, Khan A, Kim GE, Lee EY, LiVolsi VA, Longacre T, Magi-Galluzzi C, McCall SJ, McPhaul L, Mehta V, Merzianu M, Miller SB, Molberg KH, Moreira AL, Naini BV, Nosé V, O'Toole K, Picken M, Prieto VG, Pullman JM, Quick CM, Reynolds JP, Rosenberg AE, Schnitt SJ, Schwartz MR, Sekosan M, Smith MT, Sohani A, Stowman A, Vanguri VK, Wang B, Watts JC, Wei S, Whitney K, Younes M, Zee S, and Bracamonte ER
- Subjects
- Humans, Government Agencies, Pathologists, Obesity
- Published
- 2022
- Full Text
- View/download PDF
28. Molecular identification of an ETV6-RET fusion in a secretory carcinoma associated with a pleomorphic adenoma.
- Author
-
Smith ME, Surrey LF, Zhang PJ, Weinstein GS, and LiVolsi VA
- Subjects
- Humans, Proto-Oncogene Proteins c-ret, Adenoma, Pleomorphic genetics, Adenoma, Pleomorphic surgery, Carcinoma
- Abstract
Pleomorphic adenoma (PA) is the most common neoplasm of the salivary glands. Although several carcinomas have been reported to arise from PA, only 1 case of salivary gland secretory carcinoma (SC) ex pleomorphic adenoma has been previously reported. SC is a newly described salivary gland tumor harboring an ETV6-NTRK3 translocation, which is classically observed in secretory carcinoma of the breast, although other translocations have recently been observed. We report the first case of the molecular identification of a rare ETV6-RET translocation in an SC arising from a PA in the submandibular salivary gland (SC ex PA). Our results add to the diversity of tumors that are associated with PA and contribute to the molecular characterization of SC, which will have implications on its diagnosis, prognosis, and treatment., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
29. Late Recurrence of Hyperparathyroidism: Parathyromatosis or Recurrent Parathyroid Carcinoma?
- Author
-
Gubbiotti M and Livolsi VA
- Subjects
- Humans, Neoplasm Recurrence, Local, Parathyroidectomy, Chronic Disease, Syndrome, Recurrence, Parathyroid Neoplasms complications, Parathyroid Neoplasms diagnosis, Parathyroid Neoplasms surgery, Hyperparathyroidism diagnosis, Hyperparathyroidism etiology, Hyperparathyroidism surgery
- Published
- 2022
- Full Text
- View/download PDF
30. Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.
- Author
-
Randolph GW, Sosa JA, Hao Y, Angell TE, Shonka DC , Jr, LiVolsi VA, Ladenson PW, Blevins TC, Duh QY, Ghossein R, Harrell M, Patel KN, Shanik MH, Traweek ST, Walsh PS, Yeh MW, Abdelhamid Ahmed AH, Ho AS, Wong RJ, Klopper JP, Huang J, Kennedy GC, Kloos RT, and Sadow PM
- Subjects
- Biopsy, Fine-Needle, Carcinoma, Neuroendocrine, Gene Expression Profiling methods, Humans, RNA, Retrospective Studies, Thyroid Cancer, Papillary, Thyroid Neoplasms genetics, Thyroid Neoplasms pathology, Thyroid Neoplasms surgery, Thyroid Nodule genetics, Thyroid Nodule pathology, Thyroid Nodule surgery
- Abstract
Background: Cytopathological evaluation of thyroid fine-needle aspiration biopsy (FNAB) specimens can fail to raise preoperative suspicion of medullary thyroid carcinoma (MTC). The Afirma RNA-sequencing MTC classifier identifies MTC among FNA samples that are cytologically indeterminate, suspicious, or malignant (Bethesda categories III-VI). In this study we report the development and clinical performance of this MTC classifier. Methods: Algorithm training was performed with a set of 483 FNAB specimens (21 MTC and 462 non-MTC). A support vector machine classifier was developed using 108 differentially expressed genes, which includes the 5 genes in the prior Afirma microarray-based MTC cassette. Results: The final MTC classifier was blindly tested on 211 preoperative FNAB specimens with subsequent surgical pathology, including 21 MTC and 190 non-MTC specimens from benign and malignant thyroid nodules independent from those used in training. The classifier had 100% sensitivity (21/21 MTC FNAB specimens correctly called positive; 95% confidence interval [CI] = 83.9-100%) and 100% specificity (190/190 non-MTC FNAs correctly called negative; CI = 98.1-100%). All positive samples had pathological confirmation of MTC, while all negative samples were negative for MTC on surgical pathology. Conclusions: The RNA-sequencing MTC classifier accurately identified MTC from preoperative thyroid nodule FNAB specimens in an independent validation cohort. This identification may facilitate an MTC-specific preoperative evaluation and resulting treatment.
- Published
- 2022
- Full Text
- View/download PDF
31. A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
- Author
-
Brody RM, Shimunov D, Cohen RB, Lin A, Lukens JN, Hartner L, Aggarwal C, Duvvuri U, Montone KT, Jalaly JB, LiVolsi VA, Carey RM, Shanti RM, Rajasekaran K, Chalian AA, Rassekh CH, Cannady SB, Newman JG, O'Malley BW, Weinstein GS, Gimotty PA, and Basu D
- Subjects
- Benchmarking, Humans, Neoplasm Recurrence, Local epidemiology, Retrospective Studies, Head and Neck Neoplasms etiology, Oropharyngeal Neoplasms pathology, Papillomavirus Infections, Robotic Surgical Procedures adverse effects
- Abstract
Objectives: Increasing use of transoral robotic surgery (TORS) is likely to impact outcomes for HPV+ oropharyngeal squamous cell carcinomas (OPSCCs). We aimed to describe oncologic outcomes for a large HPV+ OPSCC cohort after TORS and develop a risk prediction model for recurrence under this treatment paradigm., Materials and Methods: 634 HPV+ OPSCC patients receiving TORS-based therapy at a single institution were reviewed retrospectively to describe survival across the entire cohort and for patients suffering recurrence. Risks for distant metastatic recurrence (DMR) and locoregional recurrence (LRR) were modeled using multivariate logistic regression analyses of case-control sub-cohorts., Results: 5-year overall and recurrence-free survival were 91.2% and 86.1%, respectively. 5-year overall survival was 52.5% following DMR and 83.3% after isolated LRR (P = .01). In case-control analyses, positive surgical margins were associated with DMR (adjusted OR 5.8, CI 2.1-16.0, P = .001), but not isolated LRR, and increased DMR risk 4.2 fold in patients with early clinical stage disease. By contrast, LRR was associated with not receiving recommended adjuvant therapy (OR 13.4, CI 6.3-28.5, P < .001)., Conclusions: This study sets a benchmark for oncologic outcomes from HPV+ OPSCC after TORS-based therapy. Under this treatment paradigm, margins are relevant for assessing lethal recurrence risk during clinical trial design and post-treatment surveillance., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
32. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
- Author
-
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, and Mete O
- Subjects
- DEAD-box RNA Helicases, Humans, Ribonuclease III, World Health Organization, Adenocarcinoma, Follicular pathology, Carcinoma, Neuroendocrine, Carcinoma, Papillary pathology, Thyroid Neoplasms pathology
- Abstract
This review summarizes the changes in the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new classification has divided thyroid tumors into several new categories that allow for a clearer understanding of the cell of origin, pathologic features (cytopathology and histopathology), molecular classification, and biological behavior. Follicular cell-derived tumors constitute the majority of thyroid neoplasms. In this new classification, they are divided into benign, low-risk, and malignant neoplasms. Benign tumors include not only follicular adenoma but also variants of adenoma that are of diagnostic and clinical significance, including the ones with papillary architecture, which are often hyperfunctional and oncocytic adenomas. For the first time, there is a detailed account of the multifocal hyperplastic/neoplastic lesions that commonly occur in the clinical setting of multinodular goiter; the term thyroid follicular nodular disease (FND) achieved consensus as the best to describe this enigmatic entity. Low-risk follicular cell-derived neoplasms include non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), thyroid tumors of uncertain malignant potential, and hyalinizing trabecular tumor. Malignant follicular cell-derived neoplasms are stratified based on molecular profiles and aggressiveness. Papillary thyroid carcinomas (PTCs), with many morphological subtypes, represent the BRAF-like malignancies, whereas invasive encapsulated follicular variant PTC and follicular thyroid carcinoma represent the RAS-like malignancies. This new classification requires detailed subtyping of papillary microcarcinomas similar to their counterparts that exceed 1.0 cm and recommends not designating them as a subtype of PTC. The criteria of the tall cell subtype of PTC have been revisited. Cribriform-morular thyroid carcinoma is no longer classified as a subtype of PTC. The term "Hürthle cell" is discouraged, since it is a misnomer. Oncocytic carcinoma is discussed as a distinct entity with the clear recognition that it refers to oncocytic follicular cell-derived neoplasms (composed of > 75% oncocytic cells) that lack characteristic nuclear features of PTC (those would be oncocytic PTCs) and high-grade features (necrosis and ≥ 5 mitoses per 2 mm
2 ). High-grade follicular cell-derived malignancies now include both the traditional poorly differentiated carcinoma as well as high-grade differentiated thyroid carcinomas, since both are characterized by increased mitotic activity and tumor necrosis without anaplastic histology and clinically behave in a similar manner. Anaplastic thyroid carcinoma remains the most undifferentiated form; squamous cell carcinoma of the thyroid is now considered as a subtype of anaplastic carcinoma. Medullary thyroid carcinomas derived from thyroid C cells retain their distinct section, and there is a separate section for mixed tumors composed of both C cells and any follicular cell-derived malignancy. A grading system for medullary thyroid carcinomas is also introduced based on mitotic count, tumor necrosis, and Ki67 labeling index. A number of unusual neoplasms that occur in the thyroid have been placed into new sections based on their cytogenesis. Mucoepidermoid carcinoma and secretory carcinoma of the salivary gland type are now included in one section classified as "salivary gland-type carcinomas of the thyroid." Thymomas, thymic carcinomas and spindle epithelial tumor with thymus-like elements are classified as "thymic tumors within the thyroid." There remain several tumors whose cell lineage is unclear, and they are listed as such; these include sclerosing mucoepidermoid carcinoma with eosinophilia and cribriform-morular thyroid carcinoma. Another important addition is thyroblastoma, an unusual embryonal tumor associated with DICER1 mutations. As in all the WHO books in the 5th edition, mesenchymal and stromal tumors, hematolymphoid neoplasms, germ cell tumors, and metastatic malignancies are discussed separately. The current classification also emphasizes the value of biomarkers that may aid diagnosis and provide prognostic information., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
33. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
- Author
-
Zhang X, Katsakhyan L, LiVolsi VA, Roth JJ, Rassekh CH, Bagley SJ, and Nasrallah MP
- Subjects
- Aged, DNA Methylation, DNA Modification Methylases genetics, DNA Repair Enzymes genetics, Databases, Genetic, ErbB Receptors genetics, Female, Gene Amplification, Genetic Predisposition to Disease, Humans, Isocitrate Dehydrogenase genetics, Male, Middle Aged, Phenotype, Promoter Regions, Genetic, Retrospective Studies, Tumor Suppressor Proteins genetics, Biomarkers, Tumor genetics, Brain Neoplasms genetics, Brain Neoplasms pathology, Glioblastoma genetics, Glioblastoma secondary, Mutation, Tumor Suppressor Protein p53 genetics
- Abstract
Extraneural metastases of glioblastoma (GBM), although rare, are becoming an increasingly recognized occurrence. Currently, the biological mechanism underlying this rare occurrence is not understood. To explore the potential genomic drivers of extraneural metastasis in GBM, we present the molecular features of 4 extraneural metastatic GBMs, along with a comprehensive review and analysis of previously reported cases that had available molecular characterization. In addition to our 4 cases, 42 patients from 35 publications are reviewed. To compare the molecular profiles between GBM cases with extraneural metastasis and the general GBM population, genomic data from GBM samples in The Cancer Genome Atlas (TCGA) database were also analyzed. We found that 64.5% (20/31) of the cases with extraneural metastasis that were tested for TP53 changes had at least 1 TP53 pathogenic variant detected in either 1 or both primary and metastatic tumors. In contrast, TP53 mutation was significantly less frequent in the unselected GBM from TCGA (22.6%, 56/248) (P=0.000). In addition, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation was more common in unselected TCGA GBM cases (48.6%, 170/350) than in cases with extraneural metastasis (31.8%, 7/22), although not statistically significant. Although isocitrate dehydrogenase (IDH) mutation is a rare occurrence in high-grade astrocytomas, IDH-mutant grade 4 astrocytomas are at least as likely to metastasize as IDH wild-type GBMs; 3 metastatic cases definitively harbored an IDH1 (p.R132H) mutation in our analysis. Our findings not only provide potential biomarkers for earlier screening of extraneural metastasis, but could also suggest clues to understanding biological mechanisms underlying GBM metastasis, and for the development of therapeutic modalities., Competing Interests: Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Noninvasive Follicular Tumor With Papillary-like Nuclear Features: A Practice Changer in Thyroid Pathology.
- Author
-
LiVolsi VA and Baloch Z
- Subjects
- Adenocarcinoma, Follicular genetics, Adenocarcinoma, Follicular metabolism, Biopsy, Fine-Needle, Carcinoma, Papillary genetics, Carcinoma, Papillary metabolism, Cell Nucleus genetics, Cell Nucleus metabolism, Humans, Mutation, Neoplasm Invasiveness, Thyroid Gland metabolism, Thyroid Neoplasms genetics, Thyroid Neoplasms metabolism, ras Proteins genetics, Adenocarcinoma, Follicular pathology, Carcinoma, Papillary pathology, Thyroid Gland pathology, Thyroid Neoplasms pathology
- Abstract
Context.—: This article presents a review of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), including its separation from follicular variant of papillary carcinoma of the thyroid, its evolution, and current definition and pathologic characteristics., Objectives.—: To emphasize the understanding of the concept of NIFTP as a neoplasm based on molecular analyses, its critical histopathologic features, the microscopic findings that exclude the diagnosis, and the importance of complete sectioning of the tumor to exclude neoplasms that should be diagnosed as carcinomas. Important distinctions are discussed including difficulties with literature that shows NIFTP with metastases, inadequacy of sectioning of the tumor, and lack of descriptive histology of the surrounding thyroid and possible other lesions., Data Sources.—: Review of articles in the English literature on NIFTP, as well as comparative papers showing differences and distinctions between this entity and papillary carcinomas., Conclusions.—: This article concludes that with the current state of knowledge on NIFTP with studies from all over the world, this entity is a low-risk neoplasm that, when diagnosed using appropriate criteria, should not be associated with metastatic or recurrent disease, at least on intermediate length of follow-up. This review includes discussion of multifocal NIFTP, as well as the recently defined micro-NIFTP (1 cm or less), and describes features of the tumor that remain to be studied and correlated with outcome: oncocytic variants of NIFTP, percentage of allowable solid areas of growth in the lesions, and definitions of true neoplastic papillae and hyperplastic ones and how these should influence the diagnosis of NIFTP.
- Published
- 2021
- Full Text
- View/download PDF
35. Neuroendocrine Tumors of the Thyroid and Their Mimics.
- Author
-
Livolsi VA
- Subjects
- Humans, Carcinoma, Neuroendocrine diagnosis, Thyroid Neoplasms diagnosis
- Abstract
This paper will review neuroendocrine lesions of the thyroid and the differential diagnosis with the most significant such tumor of the thyroid, that is, medullary thyroid carcinoma. A brief overview of the understanding of this tumor's identification as a lesion of C cells and its familial and syndromic associations will be presented. Then, a discussion of the various mimics of medullary carcinoma will be given with an approach to the types of tests that can be done to arrive at a correct diagnostic conclusion. This review will focus on practical "tips" for the practicing pathologist.
- Published
- 2021
- Full Text
- View/download PDF
36. A case of tumor-to-tumor metastasis of cutaneous malignant melanoma.
- Author
-
Straker RJ 3rd, Modi MB, Elder DE, LiVolsi VA, Fraker DL, Xu X, and Karakousis GC
- Subjects
- Adenoma, Oxyphilic surgery, Adenoma, Oxyphilic ultrastructure, Adult, Biopsy, Humans, Inguinal Canal pathology, Lymph Node Excision methods, Lymphadenopathy pathology, Lymphadenopathy surgery, Male, Melanoma surgery, Neoplasms, Multiple Primary pathology, Neoplasms, Second Primary pathology, Oxyphil Cells pathology, Skin Neoplasms diagnosis, Skin Neoplasms secondary, Skin Neoplasms surgery, Thyroid Neoplasms surgery, Thyroid Neoplasms ultrastructure, Thyroidectomy methods, Melanoma, Cutaneous Malignant, Adenoma, Oxyphilic diagnosis, Melanoma diagnosis, Melanoma secondary, Skin Neoplasms pathology, Thyroid Neoplasms diagnosis, Thyroid Nodule pathology
- Abstract
We report a case of tumor-to-tumor metastasis of a cutaneous malignant melanoma to a synchronous thyroid Hurthle cell carcinoma. A 42-year-old male underwent a biopsy of right inguinal lymphadenopathy which showed metastatic melanoma. The primary lesion was identified on his right posterior leg, and staging workup discovered a synchronous left thyroid lobe nodule concerning for a follicular neoplasm. He underwent excision of the primary melanoma, right inguinal lymphadenectomy, and total thyroidectomy. The resected thyroid contained a 6.6-cm, well-encapsulated left-sided nodule, red-brown in color and homogenous in consistency, with areas of focal hemorrhage and no grossly identifiable calcification. Microscopically, large tumor cells with distinct cell borders were present, with deeply eosinophilic and granular cytoplasm, large nuclei with prominent nucleoli, and loss of polarity consistent with oncocytes. A microscopic single focus of vascular invasion was identified, and a diagnosis of angioinvasive Hurthle cell carcinoma was made. Within the Hurthle cell carcinoma, multiple deposits of metastatic melanoma were seen. These findings were indicative of tumor-to-tumor metastasis of the cutaneous melanoma to the angioinvasive Hurthle cell carcinoma. Our findings show the ability of melanoma to metastasize to a pre-existing neoplasm., (© 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
37. Giant Cell Carcinosarcoma of the Parotid Gland With a PLAG 1 Translocation in Association With a Pleomorphic Adenoma With HMGA2 Translocation.
- Author
-
Katsakhyan L, LiVolsi VA, Chalian AA, and Zhang PJ
- Subjects
- Adenoma, Pleomorphic genetics, Adenoma, Pleomorphic pathology, Aged, Carcinosarcoma genetics, Carcinosarcoma therapy, Humans, In Situ Hybridization, Fluorescence, Magnetic Resonance Imaging, Male, Salivary Gland Neoplasms genetics, Salivary Gland Neoplasms therapy, Tomography, X-Ray Computed, Translocation, Genetic, Carcinosarcoma pathology, DNA-Binding Proteins genetics, Giant Cells pathology, HMGA2 Protein genetics, Parotid Gland pathology, Salivary Gland Neoplasms pathology
- Abstract
Objectives: Carcinosarcomas of the salivary gland are rare neoplasms and have been described arising de novo or in association with pleomorphic adenoma (PA). PLAG1 and HMGA2 translocations are known to occur in PAs and carcinomas ex PA but are mutually exclusive., Methods: We report a case of a carcinosarcoma in the parotid gland of a 77-year-old man with unusual anaplastic sarcomatoid giant cell morphology., Results: Microscopically, a small separate PA was found adjacent to the carcinosarcoma. By conventional notion, the PA and carcinosarcoma would be considered related, as carcinosarcomas are well known to arise from PAs (carcinosarcoma ex PA). However, fluorescence in situ hybridization (FISH) assay demonstrated PLAG1 translocation in the carcinosarcoma and HMGA2 translocation in the separate PA., Conclusions: These findings support that the carcinosarcoma likely originated from another PA with a PLAG1 translocation or de novo but not from the coexisting PA harboring a different translocation. To our knowledge, the case is the first to demonstrate PLAG1 translocation by FISH in a sarcomatous component of any parotid gland tumor, which may help better classify these tumors. In addition, multiple PAs are commonly found in the salivary gland, and to our knowledge, our case is the first to demonstrate that the same parotid gland can host PAs and PA-related tumors with different translocations., (© American Society for Clinical Pathology, 2020.)
- Published
- 2020
- Full Text
- View/download PDF
38. The Bethesda System for Reporting Thyroid Cytology (TBSRTC): From look-backs to look-ahead.
- Author
-
Baloch Z and LiVolsi VA
- Subjects
- Cytodiagnosis standards, History, 21st Century, Humans, Research Report, Thyroid Neoplasms pathology, Thyroid Nodule pathology, Clinical Trials Data Monitoring Committees history, Guideline Adherence, Thyroid Gland cytology, Thyroid Gland pathology
- Abstract
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was formalized in October 2007 by experts in thyroidology at the National Institute of Health in Bethesda, Maryland. The first edition of the TBSRTC book was published in 2010 and the second edition in 2018. The TBSRTC is widely employed in cytology practices in the United States and has also served as a model for similar tiered classification schemes for reporting thyroid cytopathology specimens. The tremendous success of TBSRTC cannot be underscored, it has provided a diagnostic framework which is well aligned with the present and the future of thyroid nodule management., (© 2020 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
39. Practice Paradigms Before and After Introduction of the Diagnosis-Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): an Institutional Experience.
- Author
-
Katsakhyan L, Song S, Lepe M, Shojaei H, Montone KT, LiVolsi VA, and Baloch ZW
- Subjects
- Adenocarcinoma, Follicular classification, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pathology, Surgical standards, Pathology, Surgical statistics & numerical data, Pathology, Surgical trends, Retrospective Studies, Thyroid Cancer, Papillary classification, Thyroid Neoplasms classification, Young Adult, Adenocarcinoma, Follicular surgery, Practice Patterns, Physicians' standards, Practice Patterns, Physicians' statistics & numerical data, Practice Patterns, Physicians' trends, Thyroid Cancer, Papillary surgery, Thyroid Neoplasms surgery, Thyroidectomy statistics & numerical data
- Abstract
The recently adopted terminology of "Noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) reflects the indolent behavior of these tumors. In contrast to conventional papillary thyroid carcinomas, NIFTP can be managed conservatively. The purpose of this study was to investigate changes in surgical and pathologic practice patterns at our institution since the introduction of the NIFTP diagnosis in 2016. A retrospective analysis of all thyroid specimens received in our laboratory between January 2015 and April 2017 was performed. The final cohort consisted of 1508 thyroidectomy specimens from 1508 patients (1153 (76.5%) women and 355 (23.5%) men), of which 1011 (67%) were total thyroidectomies and 497 (33%) were partial thyroidectomies. There were 558 (69.2%) total thyroidectomies and 248 (30.8%) partial thyroidectomies performed prior to introduction of the NIFTP diagnosis and 453 (64.5%) and 249 (35.5%) total and partial thyroidectomies, respectively, after the change in nomenclature. Within a year following the initial use of this diagnosis, 67 NIFTP cases were identified (9.5% of all thyroidectomies), whereas compared with the year preceding it, malignant diagnoses decreased from 54.5 (439) to 44.6% (313), and the benign category remained unchanged from 44.5 (367) to 45.9% (322). For the entirely submitted 67 NIFTP cases, the mean number of blocks submitted was 14.7 (0.98 blocks/g); for malignant lesions 17.7 (0.92 blocks/g); and for benign lesions 16.6 (0.75 blocks/g). The results of our study suggest that NIFTP are encountered in almost 10% of thyroidectomies at our institution with expected shifts in cytology and surgical pathology diagnoses as a result of the change in nomenclature. During this time period, significant shifts towards less aggressive surgical management were not observed. All 67 NIFTP nodules were submitted entirely with no significant difference in the number of cassettes submitted for NIFTP nodules as compared with follicular variant papillary thyroid carcinoma (PTC), classic variant PTC, or follicular adenoma.
- Published
- 2020
- Full Text
- View/download PDF
40. The significance of mucinous metaplasia in Warthin tumor: a frequent occurrence and potential pitfall.
- Author
-
Zhang X, Baloch ZW, Cooper K, Zhang PJ, Puthiyaveettil R, and LiVolsi VA
- Subjects
- Adenolymphoma genetics, Adenolymphoma surgery, Aged, Biomarkers, Tumor genetics, Carmine, Coloring Agents, Databases, Factual, Diagnosis, Differential, Female, Gene Rearrangement, Genetic Predisposition to Disease, Humans, In Situ Hybridization, Fluorescence, Male, Metaplasia, Middle Aged, Phenotype, Predictive Value of Tests, Retrospective Studies, Staining and Labeling, Trans-Activators genetics, Tumor Burden, Adenolymphoma pathology, Epithelial Cells pathology
- Abstract
Mucinous metaplasia in Warthin tumor (WT) is a recognized phenomenon. Nevertheless, its presence can create a diagnostic challenge in the distinction from the newly proposed variant of mucoepidermoid carcinoma (MEC), Warthin-like MEC. In this study, we evaluated the significance and diagnostic relevance of mucinous metaplasia in WTs. A total of 30 WTs diagnosed based on resection specimens formed the basis of this retrospective study. Mucicarmine staining was performed to identify mucinous metaplasia, and fluorescence in situ hybridization (FISH) analysis was used to detect MAML2 gene rearrangement. After review, one MAML2 rearranged case was reclassified as Warthin-like MEC as the classic bilayered epithelium in WT was not identified. The diagnosis of WT was confirmed in the remaining 29 cases. Mucinous metaplasia was encountered in 24 WTs (83%), with 14% (4/29) having an abundant amount. We found that mucinous metaplasia correlated with tumor size (p < 0.05). Age and sex distribution were similar in WT cases with or without mucinous metaplasia. In addition, neither the presence of squamous metaplasia nor the time interval between fine-needle aspiration and surgery was related to mucinous metaplasia (p > 0.05). The MAML2 FISH analyses performed in 18 WTs with variable amounts of mucinous metaplasia were negative for rearrangement. In conclusion, mucinous metaplasia is fairly common in WTs and shows a significant correlation with tumor size. Therefore, caution should be taken to avoid overinterpretation of WT with mucinous metaplasia as MEC in cases showing the classic bilayered oncocytic lining epithelium., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
41. Pathologic grading of mucoepidermoid carcinomas of the salivary gland and its effect on clinicopathologic follow-up: an institutional experience.
- Author
-
Shafique K, Zhang PJ, Montone KT, Song S, Livolsi VA, and Baloch Z
- Subjects
- Adult, Aged, Aged, 80 and over, Anoctamin-1 analysis, Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Biopsy, Carcinoma, Mucoepidermoid chemistry, Carcinoma, Mucoepidermoid genetics, Female, Gene Rearrangement, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Neoplasm Proteins analysis, Predictive Value of Tests, Retrospective Studies, Salivary Gland Neoplasms chemistry, Salivary Gland Neoplasms genetics, Trans-Activators genetics, Young Adult, Carcinoma, Mucoepidermoid pathology, Neoplasm Grading, Salivary Gland Neoplasms pathology
- Abstract
Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor. Differences inprognosis can be noted owing to the tumor grade determined using multiple grading schemes (2-tier: low- and high-grade vs. 3-tier: low-, intermediate-, and high-grade). We studied clinicopathologic features of MEC using a 3-tier grading system and retrospectively categorized cytologic diagnoses as per the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC).A total of 69 cases of MEC were identified, and most were seen in the parotid gland. Aggressive clinical behavior was seen in high-grade MEC compared with intermediate- and low-grade MEC. By fluorescence in situ hybridization (FISH) analysis, MAML2 rearrangements were seen in 78% of cases.The MSRSGC subcategorized the majority (63.8%) of MEC as salivary gland neoplasm of uncertain malignant potential, suspicious for malignancy, or malignant. Clustering intermediate- with low-grade cases did not significantly impact the clinical behavior. Both high-grade and oncocytic MEC can be MAML2 FISH negative., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
42. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.
- Author
-
Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ 3rd, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, and Carty SE
- Subjects
- Adult, Humans, United States, Endocrinology standards, Evidence-Based Medicine standards, Thyroid Diseases surgery, Thyroidectomy standards
- Abstract
Objective: To develop evidence-based recommendations for safe, effective, and appropriate thyroidectomy., Background: Surgical management of thyroid disease has evolved considerably over several decades leading to variability in rendered care. Over 100,000 thyroid operations are performed annually in the US., Methods: The medical literature from 1/1/1985 to 11/9/2018 was reviewed by a panel of 19 experts in thyroid disorders representing multiple disciplines. The authors used the best available evidence to construct surgical management recommendations. Levels of evidence were determined using the American College of Physicians grading system, and management recommendations were discussed to consensus. Members of the American Association of Endocrine Surgeons reviewed and commented on preliminary drafts of the content., Results: These clinical guidelines analyze the indications for thyroidectomy as well as its definitions, technique, morbidity, and outcomes. Specific topics include Pathogenesis and Epidemiology, Initial Evaluation, Imaging, Fine Needle Aspiration Biopsy Diagnosis, Molecular Testing, Indications, Extent and Outcomes of Surgery, Preoperative Care, Initial Thyroidectomy, Perioperative Tissue Diagnosis, Nodal Dissection, Concurrent Parathyroidectomy, Hyperthyroid Conditions, Goiter, Adjuncts and Approaches to Thyroidectomy, Laryngology, Familial Thyroid Cancer, Postoperative Care and Complications, Cancer Management, and Reoperation., Conclusions: Evidence-based guidelines were created to assist clinicians in the optimal surgical management of thyroid disease.
- Published
- 2020
- Full Text
- View/download PDF
43. Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.
- Author
-
Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ 3rd, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, and Carty SE
- Subjects
- Adult, Humans, United States, Endocrinology standards, Evidence-Based Medicine standards, Thyroid Diseases surgery, Thyroidectomy standards
- Abstract
Objective: The aim of this study was to develop evidence-based recommendations for safe, effective and appropriate thyroidectomy., Background: Surgical management of thyroid disease has evolved considerably over several decades leading to variability in rendered care. Over 100,000 thyroid operations are performed annually in the United States., Methods: The medical literature from January 1, 1985 to November 9, 2018 was reviewed by a panel of 19 experts in thyroid disorders representing multiple disciplines. The authors used the best available evidence to construct surgical management recommendations. Levels of evidence were determined using the American College of Physicians grading system, and management recommendations were discussed to consensus. Members of the American Association of Endocrine Surgeons reviewed and commented on preliminary drafts of the content., Results: These clinical guidelines analyze the indications for thyroidectomy as well as its definitions, technique, morbidity, and outcomes. Specific topics include Pathogenesis and Epidemiology, Initial Evaluation, Imaging, Fine Needle Aspiration Biopsy Diagnosis, Molecular Testing, Indications, Extent and Outcomes of Surgery, Preoperative Care, Initial Thyroidectomy, Perioperative Tissue Diagnosis, Nodal Dissection, Concurrent Parathyroidectomy, Hyperthyroid Conditions, Goiter, Adjuncts and Approaches Laryngology Familial Thyroid Cancer, Postoperative Care and Complications, Cancer Management, and Reoperation., Conclusion: Evidence-based guidelines were created to assist clinicians in the optimal surgical management of thyroid disease.
- Published
- 2020
- Full Text
- View/download PDF
44. Fifty years of thyroid pathology: concepts and developments.
- Author
-
Baloch Z and LiVolsi VA
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor history, Diffusion of Innovation, Genetic Predisposition to Disease, History, 20th Century, History, 21st Century, Humans, Thyroid Diseases genetics, Thyroid Diseases history, Pathology history, Pathology trends, Pathology, Molecular history, Pathology, Molecular trends, Thyroid Diseases pathology, Thyroid Gland pathology
- Abstract
The past half century has seen a number of advances in pathology of thyroid diseases, especially neoplastic lesions. These include the description of new entities, the definition of prognostically important lesions, the incorporation of fine needle aspiration biopsy and its functional risk stratification of diagnoses into the clinical evaluation and therapeutic recommendations of the patient with thyroid nodules and the understanding of thyroid neoplastic development, diagnostic and prognostic parameters by use of molecular analysis so that such techniques are becoming standard of care for patients with thyroid tumors. The histopathologist and cytopathologist have been and continue to be at the forefront in the definition and understanding of these areas of thyroid disease. This review describes many of the most important advances in this area in an attempt bring the practicing pathologist up to date in these developments., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
45. Recurrent glomangioma ("true" glomus tumor) of the middle ear and mastoid.
- Author
-
Kaufman AC, Brant JA, Luu NN, LiVolsi VA, and Bigelow DC
- Abstract
Objective: To review current literature and experience with glomangiomas, or true glomus tumors of the middle ear and mastoid as well asto report on the exceptionally rare case of a glomangiomastemming from the middle ear space with multiple recurrences., Methods: Review of existing world literature and description of personal experience with rare cases of a glomangioma of the middle ear and mastoid., Results: Review of existing literature revealed two cases of patients presenting with tinnitus and hearing loss refractory to medical management. Both patients were ultimately diagnosed with glomangioma on histopathology. Complete surgical excision is thought to be curative., Patient: A 36-year-old woman presented with a rare case of a glomangioma of the middle ear presenting with unilateral hearing loss. She was noted to have a mass behind the tympanic membrane. Imaging revealed a diffuse mass filling the mastoid air cells. Imaging characteristics and histology were consistent with a glomangioma., Intervention: Initial resection via mastoidectomy using a postauricular approach. The tympanic membrane was reconstructed with temporalis tissue. Follow-up revision tympanomastoidectomy was performed upon recurrence of disease. The chorda tympani were sacrificed due to tumor involvement. The incus and head of the malleus were removed to gain better access to the tumor. The ossicular chain was reconstructed with a Goldenberg Total Ossicular Prosthesis., Main Outcome Measure: Recurrence of disease., Follow-Up: In the 67 months since her most recent surgery, there has been no evidence of recurrence by CT or physical exam., Conclusion: Glomangioma of the middle ear represents an exceptionally rare entity that can present in a similar fashion to a paraganglioma., Competing Interests: The authors have no funding, financial relationships, or conflicts of interest to disclose., (© 2019 The Authors.)
- Published
- 2019
- Full Text
- View/download PDF
46. The evolving landscape of HPV-related neoplasia in the head and neck.
- Author
-
Devins KM, Tetzlaff MT, Baloch Z, and LiVolsi VA
- Subjects
- Biomarkers, Tumor analysis, Cyclin-Dependent Kinase Inhibitor p16 analysis, Diagnosis, Differential, Head and Neck Neoplasms epidemiology, Head and Neck Neoplasms pathology, Host-Pathogen Interactions, Humans, Papillomavirus Infections diagnosis, Papillomavirus Infections epidemiology, Predictive Value of Tests, Prognosis, Squamous Cell Carcinoma of Head and Neck epidemiology, Squamous Cell Carcinoma of Head and Neck pathology, Cell Transformation, Viral, Head and Neck Neoplasms virology, Papillomaviridae pathogenicity, Papillomavirus Infections virology, Squamous Cell Carcinoma of Head and Neck virology
- Abstract
Human papilloma virus (HPV) has emerged as the key etiologic driver in the majority of cancers at head and neck mucosal sites. First described in the uterine cervix and subsequently in oropharyngeal squamous cell carcinomas, the morphologic and clinical spectrum of HPV-related neoplasia has continued to expand and now includes a newly described entity in the sinonasal tract. A recent study has also suggested a role of HPV in some ocular adnexal sebaceous carcinomas. Herein, we review and concisely summarize the spectrum of HPV-driven neoplasia in the head and neck, with a focus on variant morphologies and newly-described entities including key differential diagnoses and clinical implications., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. Pembrolizumab-Induced Thyroiditis.
- Author
-
Imblum BA, Baloch ZW, Fraker D, and LiVolsi VA
- Subjects
- Adult, Antibodies, Monoclonal, Humanized therapeutic use, Antithyroid Agents therapeutic use, Carcinoma, Small Cell complications, Carcinoma, Small Cell drug therapy, Female, Graves Disease chemically induced, Graves Disease prevention & control, Humans, Methimazole therapeutic use, Ovarian Neoplasms complications, Ovarian Neoplasms drug therapy, Thyroid Gland diagnostic imaging, Thyroid Gland pathology, Thyroidectomy, Thyroiditis diagnostic imaging, Thyroiditis pathology, Antibodies, Monoclonal, Humanized adverse effects, Thyroiditis chemically induced
- Abstract
Immune checkpoint inhibitors act to restore T cell-mediated antitumor immunity. By this nature, these cancer immunotherapy drugs are associated with various immune-related adverse events such as thyroid dysfunction. We describe a case of thyrotoxicosis secondary to a programmed cell death 1 (PD-1) immune checkpoint inhibitor, pembrolizumab. A 30-year-old female was started on pembrolizumab immunotherapy for stage III small cell carcinoma of the ovary, hypercalcemic type. Thirteen days after her second cycle of therapy, she presented with symptoms consistent with thyrotoxicosis. A thyroiditis was diagnosed by thyroid function tests and ultrasonography. She was originally treated with prednisone and metoprolol for possible Grave's disease. Pertechnetate thyroid scan was more consistent with thyroiditis secondary to pembrolizumab. She underwent a total thyroidectomy 10 days after initial presentation for refractory thyrotoxicosis despite maximal medical therapy. Her symptoms resolved and thyroid function tests significantly improved. Pathology was consistent with severe thyroiditis. Immune microenvironment may play a role in the expression of programmed cell death protein 1 ligand 1 (PD-L1). Chronic inflammation surrounding tumor upregulates PD-L1 expression on tumor cells by the release of cytokines, which acts to inhibit tumor destruction. We suggest that our patient had an undetected chronic inflammation of the thyroid, specifically Hashimoto's thyroidits, which predisposed her to thyroid destruction when taking pembrolizumab. Understanding that an inflammatory environment impacts thyroid toxicity to PD-1 inhibitor therapy is novel and should be further studied.
- Published
- 2019
- Full Text
- View/download PDF
48. Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging.
- Author
-
Turk AT, Asa SL, Baloch ZW, Faquin WC, Fellegara G, Ghossein RA, Giordano TJ, LiVolsi VA, Lloyd R, Mete O, Rosai J, Suster S, Thompson LDR, and Wenig BM
- Subjects
- Carcinoma, Papillary pathology, Humans, Lymphatic Metastasis, Neoplasm Staging, Observer Variation, Thyroid Gland pathology, Thyroid Neoplasms pathology
- Abstract
Background: Extrathyroidal extension (ETE) by papillary and follicular thyroid carcinoma can be associated with increased risk of tumor recurrence and mortality. In the seventh edition of its Cancer Staging Manual, the American Joint Committee on Cancer (AJCC) defined minimal ETE as the involvement of skeletal muscle (i.e., strap muscles) or perithyroidal soft tissue. The eighth edition of the AJCC Cancer Staging Manual has changed the criteria so that only grossly evident (macroscopic) ETE involving strap muscles (not microscopic ETE involving perithyroidal soft tissue) affects tumor staging. Summary: Concordance of identifying microscopic ETE (as well as extranodal extension by carcinoma metastatic to lymph nodes) was previously evaluated among 11 expert endocrine pathologists. The overall agreement rate was slight when rendering a diagnosis of ETE. Concordance was highest when pathologists assessed the spatial relationship of carcinoma to skeletal muscle. This article discusses the significance of these findings. It also reviews relevant anatomic and developmental considerations related to the boundaries of the thyroid. Conclusions: The results of the concordance study provide additional rationale supporting stringent criteria for diagnosing ETE, as proposed by the eighth edition of the AJCC Cancer Staging Manual. It is expected that these rigid morphologic criteria will potentially reduce interobserver variability and enhance consistency in the diagnosis and staging of thyroid carcinoma.
- Published
- 2019
- Full Text
- View/download PDF
49. The utility of the Milan System as a risk stratification tool for salivary gland fine needle aspiration cytology specimens.
- Author
-
Song SJ, Shafique K, Wong LQ, LiVolsi VA, Montone KT, and Baloch Z
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biopsy, Fine-Needle, Child, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Neoplasms pathology, Risk Assessment, Salivary Gland Neoplasms pathology, Salivary Glands pathology, Specimen Handling, Thyroid Gland pathology, Thyroid Neoplasms pathology, Young Adult, Cytodiagnosis, Neoplasms diagnosis, Salivary Gland Neoplasms diagnosis, Thyroid Neoplasms diagnosis
- Abstract
Objective: To perform a retrospective investigation of our institutional experience with salivary gland fine needle aspirations (FNA) through the framework of The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) and assess the risks of neoplasm and malignancy for each diagnostic category., Methods: All salivary gland FNAs performed from January 2009 to December 2016 were retrospectively categorised according to the MSRSGC. When available, pre-operative cytological results were correlated with subsequent histological follow-up., Results: In total, 893 FNAs were reviewed. The specimens were retrospectively classified as nondiagnostic (ND: 13.5%), non-neoplastic (NN: 16.1%), atypia of undetermined significance (AUS: 10.8%), benign neoplasm (BN: 34.9%), salivary gland neoplasm of uncertain malignant potential (SUMP: 8.2%), suspicious for malignancy (SM: 2.7%) and malignant (M: 13.8%). Histological follow-up was available for 429 cases (48%); the majority (68.1%) were benign. The risks of neoplasm and malignancy for each category were as follows: ND: 64.5%, 16.1%; NN: 42.9%, 17.9%; AUS: 79.6%, 30.6%; BN: 100%, 2.2%; SUMP: 100%, 46.6%; SM: 94.7%, 78.9%; and M: 100%, 98.5%., Conclusions: The MSRSGC is a useful classification scheme for stratifying salivary gland lesions according to their associated risk of malignancy and guiding clinicians toward appropriate management. Diagnostic pitfalls are seen in a small proportion of cases and a multidisciplinary approach for assessing salivary gland pathology is essential in their evaluation., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
50. The Pathology of Hyperthyroidism.
- Author
-
LiVolsi VA and Baloch ZW
- Abstract
This article reviews those pathologic lesions which are associated with clinical and/or biochemical hyperthyroidism. Beginning with the descriptive pathology of classical Graves' disease and the less common toxic nodular goiter and hyper-functioning thyroid nodules, this paper describes the effects of non-thyroidal hormones, glandular function (including pituitary and hypothalamic lesions), ectopic production of thyroid stimulating proteins by non-thyroidal neoplasms, exogenous drug reactions causing hyper-function and finally conditions associated with a mechanic- destructive cause of hyperthyroidism.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.